Vanguard Fiduciary Trust
APLS

Vanguard Fiduciary Trust’s Apellis Pharmaceuticals APLS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-654,922
Closed -$26.3M – 4081
2026
Q1 		$26.3M Buy
+654,922
New +$14.1M 0.01% 1149

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Fiduciary Trust's APLS Position: Q2 2026 in Review

Vanguard Fiduciary Trust sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 654,922 shares — an estimated $26.3M sold.

Vanguard Fiduciary Trust first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $26.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Vanguard Fiduciary Trust reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Fiduciary Trust sold 654,922 Apellis Pharmaceuticals shares in Q2 2026, an estimated $26.3M.
  • Vanguard Fiduciary Trust first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Fiduciary Trust's Apellis Pharmaceuticals position peaked at $26.3M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.